Search the Newsreel

Sionna Therapeutics, Inc. - Common Stock (SION) Stock Price, News, Quote & History

Sionna Therapeutics (SION) halted development of SION-719 after its Phase 2a study failed to meet the key activity endpoint for cystic fibrosis treatment, despite initially showing promise. The company is now focusing on the SION-451 combination path. This news follows previous reports on financial …

Fusion Fuel Green (HTOO) updates August 2026 PIPE and restructures legal fee obligations

Fusion Fuel Green PLC has updated the terms of its August 2026 private placement (PIPE), restating the number of Class A ordinary shares and warrants to be issued for approximately $1,525,000 in gross proceeds. The company also restructured its legal fee obligations with Bevilacqua …

Intrusion Inc. (INTZ) warns on going concern as losses mount and debt rises

Intrusion Inc. reported a significant deepening of its Q2 2026 net loss, with revenue declining by 22% for the quarter and 36% year-to-date compared to 2025. The company's cash and cash equivalents dwindled to $0.2 million, leading management to express substantial doubt about its …

Allison Transmission Keeps Quarterly Dividend at $0.29 per Share, Payable Aug. 31 to Holders of Record Aug. 21

Allison Transmission Holdings, Inc. announced that it will maintain its quarterly dividend at $0.29 per share. This dividend is payable on August 31 to shareholders of record as of August 21. The announcement was made on August 11, 2026, at 05:33 pm EDT.

Allison Declares Quarterly Dividend

INDIANAPOLIS, Aug. 11, 2026 /PRNewswire/ -- Allison Transmission Holdings Inc. (NYSE: ALSN), a global leader in high-performance mobility and work solutions built for the needs of the modern industrial world, announced today that its Board of Directors has declared a cash dividend of $0.29 …

Allison Transmission (ALSN) holder to sell 1,050 shares from vested award

A holder of Allison Transmission Holdings Inc. (ALSN) common stock plans to sell 1,050 shares through Merrill Lynch on the NYSE. These shares, valued at $131,250.00, were acquired on February 28, 2024, from the vesting of a performance share unit award. The planned sale …

Intrusion Inc. (NASDAQ: INTZ) Q2 2026 results show ARR boost but tight cash

Intrusion Inc. reported Q2 2026 revenues of $1.5 million, a 64% sequential increase but a 22% year-over-year decrease, resulting in a net loss of $2.6 million. The company's cash position is tight at $0.2 million, but the recent acquisition of VigilAigent is expected to …

Intrusion Inc. Reports Second Quarter 2026 Results

Intrusion Inc. announced its financial results for the second quarter ended June 30, 2026, reporting sequential revenue growth of 64% and highlighting the strategic acquisition of VigilAigent. This acquisition is expected to add approximately $3.5 million in annual recurring revenue and enhance the company's …

USA Compression Partners, LP Common Units (USAC) Presents at Citi's 2026 Natural Resources Conference - Slideshow (NYSE:USAC) 2026-08-11

USA Compression Partners, LP Common Units (USAC) presented a slideshow at Citi's 2026 Natural Resources Conference. The article provides access to the slide deck published by the company in conjunction with this event. It also notes recent Q2 2026 earnings, where EPS missed estimates …

General Fusion at canaccord growth conference: practical fusion push By Investing.com

General Fusion presented at Canaccord Genuity’s 46th Annual Growth Conference, outlining its magnetized target fusion approach as a practical path to commercial power. The company highlighted its significant funding, including CAD $100 million from the Canadian government, and its ongoing LM26 demonstration program aimed …

GFUZ: Magnetized target fusion and liquid metal technology drive practical, scalable fusion power

General Fusion Group Ltd. (GFUZ) is making strides in fusion energy through its approach using magnetized target fusion and a liquid metal wall. This technology aims to provide practical and cost-competitive fusion power by addressing key industry challenges. The company is advancing towards commercial …

Diffusion Engineers Q1FY27 consolidated PAT rises 36% on revenue surge

Ecogas Inversiones S.A. presenta sus resultados del segundo trimestre y del primer semestre de 2026

Mission Produce vs. Dole: Which Fresh Produce Stock Looks Stronger?

This article compares Mission Produce (AVO) and Dole plc (DOLE), two key players in the fresh produce market, highlighting their distinct business models. Mission Produce focuses on avocados with growing interests in blueberries and mangoes, while Dole operates a broader, diversified global fresh produce …

SION Stock Slides, Then Snaps Back As Traders Eye Volatility

Sionna Therapeutics Inc. (SION) stock experienced significant volatility, plunging from mid-$50s to around $5 before bouncing back intraday. Despite burning cash, the company boasts a strong balance sheet with $211.0M in cash and low debt, providing a substantial runway for its early-stage biotech strategy. …

Future Vision II Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

USA Compression Q2 Earnings & Revenues Beat Estimates, Rise Y/Y

USA Compression Partners (USAC) reported strong second-quarter 2026 results, surpassing Zacks Consensus Estimates for both adjusted net profit and revenues. The company's adjusted net profit rose to 31 cents per common unit, and revenues increased by 36.8% year-over-year to $342.1 million, driven by higher …

Is USAC Worth Buying for Growth Despite Margin and Leverage Risks?

USA Compression Partners (USAC) shows strong growth visibility with future fleet commitments, supporting its bull case for horsepower expansion. However, the company faces risks from declining adjusted gross margins due to a less favorable business mix, substantial leverage, and high capital needs for expansion. …

Entravision Communications (NYSE:EVC) Shares Gap Down - Should You Sell?

Sionna Therapeutics, Inc. (SION) Shares Plummet Following Clinical Trial Results—Johnson Fistel Investigates

Johnson Fistel, PLLP is investigating Sionna Therapeutics, Inc. (SION) for potential violations of federal securities laws after the company's shares plummeted following disappointing Phase 2a clinical trial results for SION-719. The trial failed to show meaningful improvement in cystic fibrosis, leading Sionna to halt …

National Vision Holdings (EYE) Could Be 23% Below Fair Value On Premium Product Mix

Keen Vision Acquisition Corporation Units (NASDAQ

Fusion Finance shareholders approve promoter reclassification to public category

Sionna Therapeutics stock falls 92% after SION-719 trial failure

Sionna Therapeutics experienced a 92% stock drop after its experimental cystic fibrosis drug, SION-719, failed to meet its key endpoint in a Phase 2a trial. The company will not advance SION-719 as an add-on therapy and is evaluating its SION-451 program, while considering workforce …

National Vision earnings on deck after Q1 beat raised bar

National Vision Holdings Inc. is set to report Q2 earnings, with analysts expecting a sequential decline in EPS and revenue compared to a strong Q1. Investors will be monitoring whether the anticipated Q2 dip is normal seasonality or indicative of deeper challenges to the …

Future Vision II Acquisition Corp. Q2 2026: Net income $410K, EPS $0.1— 10-Q Summary

Future Vision II Acquisition Corp. (FVN) reported a net income of $410K for Q2 2026, a decrease from $552K in the prior year, with diluted earnings per share at $0.1. The company is a blank-check SPAC with no operating revenues, and its income consists …

Future Vision II (FVN) earns $0.83M on trust, faces 2026 merger deadline

Future Vision II Acquisition Corp. (FVN) reported a net income of $828,741 for the six months ending June 30, 2026, primarily from income on its Trust Account's marketable securities. The SPAC faces a critical deadline of September 13, 2026, to complete its merger with …

SIONNA THERAPEUTICS, INC. : WEDBUSH CUTS TO NEUTRAL FROM OUTPERFORM; CUTS TARGET PRICE TO $5 FROM $53

Wedbush has downgraded Sionna Therapeutics Inc. (SION.O) from Outperform to Neutral and significantly cut its target price from $53 to $5. This revision reflects a more cautious outlook from the analyst firm regarding the biopharmaceutical company's prospects.

Precision Camshafts Q1 Results: EBITDA Halves YoY, Net Profit Falls 42%

Equities Analysts Offer Predictions for PRAX Q3 Earnings

HC Wainwright has revised its Q3 2026 EPS estimate for Praxis Precision Medicines (NASDAQ:PRAX) to a loss of $3.86 per share, maintaining a "Buy" rating and a $1,201 price target, indicating expectations for profitability by Q4 2027. Several other analysts also weighed in on …

Entravision Communications Corporation Announces Quarterly Dividend of $0.05 (NYSE:EVC)

Diffusion Engineers Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Diffusion Engineers consolidated net profit rises 36.26% in the June 2026 quarter

Raj Television Network posts Q1 FY27 net loss of ₹1.01 crore

Dekel Agri-Vision director lifts stake with premium-priced share purchase

Fusion Finance shares a Buy after Q1 results? What CLSA, ICICI Sec, IIFL, MOFSL, JM say